lucky max numbers

New Delhi, Dec 26 (PTI) Manmohan Singh, the architect of India’s economic reforms, had to literally face a trial-by-fire to ensure widespread acceptance of his path-breaking Union Budget of 1991 that saw the nation rise from its darkest financial crises. Singh, the newly-appointed finance minister in the P V Narasimha Rao-led government, did it with great elan — from facing journalists at a post-budget press conference and irate Congress leaders at the parliamentary party meeting who were unable to digest the wide-ranging reforms. Singh’s historic reforms in 1991 not only rescued India from near bankruptcy but also redefined its trajectory as a rising global power. Singh made an unscheduled appearance at the press conference on July 25, 1991, a day after the presentation of the Union Budget “to ensure that the message of his budget did not get distorted by less-than-enthusiastic officials”, Congress leader Jairam Ramesh writes in his book ‘To the Brink and Back: India’s 1991 Story’ that recounts the fast-paced changes that took place after Rao became the prime minister in June 1991. “The finance minister explained his budget — calling it ‘a budget with a human face’. He painstakingly defended the proposals to increase fertiliser, petrol and LPG prices,” Ramesh recounts in the book published in 2015. Ramesh was an aide to Prime Minister Rao during his initial months in office. Sensing the disquiet among the Congress ranks, Prime Minister Rao called a meeting of the Congress Parliamentary Party (CPP) on August 1, 1991 and decided to allow party MPs to “vent their spleen freely”. “The prime minister stayed away and allowed Manmohan Singh to face the flak on his own,” Ramesh writes, adding that two more meetings took place on August 2 and 3, in which Rao was present throughout. “In the CPP meetings, the finance minister cut a lonely figure and the prime minister did nothing to alleviate his distress,” Ramesh recounts. Only two MPs — Mani Shankar Aiyar and Nathuram Mirdha — backed Manmohan Singh’s budget wholeheartedly. Aiyar had supported the budget, contending that it conformed to Rajiv Gandhi’s beliefs on what needed to be done to stave off the financial crisis. Bowing to pressure from the party, Singh had agreed to lower the 40 per cent increase in fertilser prices to 30 per cent, but had left the hike in LPG and petrol prices untouched. The Cabinet Committee on Political Affairs met twice on August 4 and 5, 1991 to decide on the statement Singh would make in the Lok Sabha on August 6. “The statement dropped the idea of a roll-back which had been demanded over the past few days, but now spoke of protecting the interests of small and marginal farmers,” the book states. “Both sides had won. The party had forced a rethink, but the fundamentals of what the government wanted — the decontrol of prices of fertilisers other than urea and an increase in urea prices — had been preserved,” Ramesh recounts. “This was political economy at its constructive best — a textbook example of how the government and the party can collaborate to create a win-win situation for both,” the book states. PTI SKU SKY SKY This report is auto-generated from PTI news service. ThePrint holds no responsibility for its content. var ytflag = 0;var myListener = function() {document.removeEventListener('mousemove', myListener, false);lazyloadmyframes();};document.addEventListener('mousemove', myListener, false);window.addEventListener('scroll', function() {if (ytflag == 0) {lazyloadmyframes();ytflag = 1;}});function lazyloadmyframes() {var ytv = document.getElementsByClassName("klazyiframe");for (var i = 0; i < ytv.length; i++) {ytv[i].src = ytv[i].getAttribute('data-src');}} Save my name, email, and website in this browser for the next time I comment. Δ document.getElementById( "ak_js_1" ).setAttribute( "value", ( new Date() ).getTime() );President-elect Donald Trump's pick for health secretary, Robert F. Kennedy Jr., said Thursday he believes anti-obesity drugs "have a place." The comment, given in a brief interview to CNBC off the floor of the New York Stock Exchange, was the strongest suggestion yet that, if confirmed to take over the Department Health and Human Services, Kennedy wouldn't necessarily move to block access to a class of drugs that he's sharply criticized in the past but that doctors are hailing as a powerful tool in the obesity epidemic. When asked how he felt by drugs that mimic the actions of the GLP-1 hormone, Kennedy said "the first line of response should be lifestyle, it should be eating well, making sure that you don't get obese, and that those GLP drugs have a place." MORE: Elon Musk shows support for weight loss drugs despite RFK Jr.'s criticism Kennedy's aside comes one day after Trump adviser Elon Musk said he believes "nothing would do more to improve the health, lifespan and quality of life for Americans than making GLP inhibitors super low cost to the public." The seeming endorsement of medications such as Ozempic, Wegovy, Mounjaro and Zepbound from two people who have Trump's ear is likely to be a relief for the pharmaceutical industry following Kennedy's sharp questioning of America's reliance on weight-loss medications. Previously, Kennedy has said that if America paid more for quality food, it would solve the obesity crisis "overnight" -- a statement obesity experts criticized as overly simplistic. MORE: Active ingredient in Ozempic, Wegovy may reduce risk of Alzheimer's disease: Study Still in question is how the incoming administration plans to handle coverage of the drugs through Medicare and Medicaid and any regulation of the private insurance industry. The Biden administration has called for Medicare and Medicaid to expand coverage of weight-loss drugs for people struggling with obesity, not just as a treatment for diabetes. But because that rule won't kick in until 2026, it'll be up to the incoming administration to enact. Covering GLP-1 drugs under federal health insurance programs would come at a significant cost to the country. The Congressional Budget Office estimates that expanding coverage of anti-obesity drugs in Medicare alone would increase federal spending by about $35 billion from 2026 to 2034. Calley Means, a top adviser to Kennedy, has criticized the Biden proposal's embrace of weight-loss drugs instead of pushing lifestyle changes and suggested that the incoming administration should work on "benefit flexibility where patients can work with their doctors on the best solution to reverse obesity for them," including "lifestyle coaching, food interventions, or, in some cases, drugs." Means also said the government should ensure the price mirrors European costs. "The problem isn't that Ozempic exists," Means tweeted on Thursday. "It is the fact that this Danish company has been able to pay US regulators, media, and lawmakers to force this drug down our throats as the only option." In the CNBC interview on Thursday, Kennedy also reiterated his stance that he doesn't oppose all vaccines. While Kennedy has said he's not opposed to all vaccines, he has falsely claimed that childhood vaccines cause autism, despite the retraction of the fraudulent study that originally suggested this link, and numerous subsequent high-quality studies disproving this theory. In a Time magazine interview, Trump said the issue of vaccine safety still warrants a "big discussion" and that he would be open to restricting some vaccines if Kennedy found them "dangerous." Kennedy has said he is "fully vaccinated," except against COVID-19.lucky max numbers 。

NFL fans are all saying the same thing as Daniel Jones is listed on Cowboys roster after Giants release

MENLO PARK, Calif., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Sight Sciences , Inc. SGHT ("Sight Sciences," or the "Company"), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard of care, today announced the results of a Budget Impact Analysis ("BIA") of the TearCare ® System ("TearCare") for the treatment of MGD-associated dry eye disease ("DED") in the United States. A BIA estimates the fiscal impact of adopting a new technology or treatment within a specific provider environment or patient population – in this case, identifying the health savings associated with increased adoption of TearCare as compared to prescription dry eye medications for patients with DED.* The analysis, projected over a two-year period, focused on moderate to severe MGD- associated DED in U.S. patients over 18 years of age. It compared the financial impact of TearCare to commonly prescribed dry eye medications, including Restasis 0.05% branded and generic, and Xiidra 5%. Key findings indicated that a 20% increase in market share of TearCare compared to prescription dry eye medications would yield an estimated annual savings of $36.87 per member per year ("PMPY") in a hypothetical health plan with one million covered lives. The study showed a direct relationship between increased utilization of TearCare in place of prescription medications and total costs savings from a US payer perspective. "In addition to the strong clinical efficacy of TearCare shown in the SAHARA and OLYMPIA randomized controlled trials, this budget impact analysis reported that increased adoption of TearCare treatments for patients with MGD-associated DED was estimated to result in meaningful cost savings. We believe the combination of the strong clinical data from the SAHARA RCT and the findings of this budget impact analysis create a compelling case for payors to cover treatments performed with TearCare at an appropriate reimbursement level," said Paul Badawi, Co-Founder and Chief Executive Officer of Sight Sciences. "Pioneering market access to interventional dry eye treatments with TearCare on behalf of patients and the eye care providers who care for them is a core component of our strategy and this milestone represents progress towards delivering this innovative technology to a portion of the 17.9 million patients diagnosed with dry eye disease in the U.S." Authors and affiliations : Phoenix Riley, PharmD, MSc (AESARA, Inc.); Cristina Masseria, PhD (AESARA, Inc.); Chad Patel, PharmD (AESARA, Inc.); Roberta Longo, PhD (AESARA, Inc.); Lorie Mody, PharmD (AESARA, Inc.), and Thomas Chester, OD, FAAO (Cleveland Eye Clinic). *The BIA was developed in accordance with established ISPOR guidelines, but it was based upon various assumptions, including with respect to cost of treatments, respective usage and market uptake of prescription drops and TearCare, efficacy (including duration of effect), safety and similar factors. These assumptions may not be consistent with actual clinical and market conditions, and changes in one or more of these assumptions could cause individual health plan results to differ. Paper Reference: Chester, T., Longo, R., Masseria, C., Riley, P., Patel, C., & Mody, L. (2024). Budget impact analysis (BIA) of the TearCare System for the treatment of meibomian gland dysfunction (MGD)-associated dry eye disease (DED) in the United States (US). Expert Review of Ophthalmology , DOI: 10.1080/17469899.2024.2444930. About Sight Sciences Sight Sciences is an eyecare technology company focused on developing and commercializing innovative and interventional solutions intended to transform care and improve patients' lives. Using minimally invasive or non-invasive approaches to target the underlying causes of the world's most prevalent eye diseases, Sight Sciences seeks to create more effective treatment paradigms that enhance patient care and supplant conventional outdated approaches. The Company's OMNI ® Surgical System is an implant-free glaucoma surgery technology (i) indicated in the United States to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and (ii) CE Marked for the catheterization and transluminal viscodilation of Schlemm's canal and cutting of the trabecular meshwork to reduce intraocular pressure in adult patients with open-angle glaucoma. Glaucoma is the world's leading cause of irreversible blindness. The Company's SION ® Surgical Instrument is a bladeless, manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork. The Company's TearCare System technology is 510(k) cleared in the United States for the application of localized heat therapy in adult patients with evaporative dry eye disease due to Meibomian Gland Disease ("MGD") when used in conjunction with manual expression of the meibomian glands, enabling clearance of gland obstructions by eyecare providers to address the leading cause of dry eye disease. For more information, visit www.sightsciences.com . Sight Sciences, the Sight Sciences logo, TearCare, SmartHub and SmartLids are trademarks of Sight Sciences registered in the United States. OMNI and SION are trademarks of Sight Sciences registered in the United States, European Union and other territories. © 2024 Sight Sciences. All rights reserved. Forward-Looking Statements This press release, together with other statements and information publicly disseminated by the Company, contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The Company intends such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995 and includes this statement for purposes of complying with these safe harbor provisions. Any statements made in this press release that are not statements of historical fact, including statements about our beliefs and expectations, are forward-looking statements and should be evaluated as such. Forward-looking statements include, without limitation statements regarding estimated costs savings associated with use of the TearCare System; and the belief that the findings of this budget impact analysis create a compelling case for payors to cover treatments performed with TearCare at an appropriate reimbursement level. These statements often include words such as "anticipate," "expect," "suggests," "plan," "believe," "intend," "estimates," "targets," "projects," "should," "could," "would," "may," "will," "forecast" and other similar expressions. We base these forward-looking statements on our current expectations, plans and assumptions that we have made in light of our experience in the industry, as well as our perceptions of historical trends, current conditions, expected future developments and other factors we believe are appropriate under the circumstances at such time. Although we believe that these forward-looking statements are based on reasonable assumptions at the time they are made, you should be aware that many factors could affect our business, results of operations and financial condition and could cause actual results to differ materially from those expressed in the forward-looking statements. These forward-looking statements are subject to and involve numerous risks, uncertainties and assumptions, including those discussed under the caption "Risk Factors" in our filings with the U.S. Securities and Exchange Commission, as may be updated from time to time in subsequent filings, and you should not place undue reliance on these statements. These cautionary statements are made only as of the date of this press release. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law. Media contact pr@SightSciences.com Investor contact: Philip Taylor Gilmartin Group 415.937.5406 Investor.Relations@Sightsciences.com © 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.Stock market today: Wall Street ends little changed after giving up a big morning gainCraig Wright Claimed to Have Invented Bitcoin, Found in Contempt of Court